Two key obstacles to efficient experimental therapeutics for cognitive impairment (CI) associated with Parkinson's disease (PD) are lack of accurate prediction of which patients are at highest risk for CI in the near term, and heterogeneity in the pathology underlying CI in PD and Parkinson's disease dementia (PDD). Project 1 will address both of these critical issues. The first goal of the project is to improve the ability to predict which patients with PD are at highest risk for developing CI by building a predictive model that combines clinical and biomarker data. The second goal of the project is to better understand potential pathological subtypes of dementia in PDD and Lewy Body Dementia (LBD) by examining patterns of expression of clinical and biomarker features which may reflect different underlying pathology.
The specific aims of Project 1 are: 1) to replicate previously-reported candidate biomarkers of CI in a training cohort of LBSD patients;2) to define relationships among candidate biomarkers in Aim 1 to identify potential pathophysiological subtypes of cognitive impairment in PD and DLB;and 3) to develop a multimodal predictive algorithm for cognitive decline in PD and apply it to an independent test cohort of PD patients. We will accomplish these aims in the context of longitudinal cohort study that uses data already collected in the first funding cycle of the Penn Udall Center along with additional data collected in this cycle. We will use Hierarchical Cluster Analysis and Principal Components Analysis to examine patterns of clinical and biomarker expression. We will use a split-sample approach to developing and testing the predictive algorithm. The products of this study will be a deeper understanding of the inter-relations of clinical and biological features of CI in PD and a practical tool for assessing the risk of developing this disabling complication.
Parkinson's disease (PD) is a common neurodegenerative disease affecting approximately 1 million Americans. While the motor symptoms of PD are well-recognized and can be targeted by effective symptomatic medications, cognitive impairment and dementia in PD are common (affecting 80% of patients with PD for 20 years), costly, and without effective symptomatic therapies. This project seeks to develop clinically useful biomarkers for predicting and monitoring the development of cognitive impairment in PD, thus removing significant roadblocks to the development of effective therapies for this important, currently untreatable, aspect of disease.
|Brennan, Laura; Siderowf, Andrew; Rubright, Jonathan D et al. (2016) The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. Parkinsonism Relat Disord 25:21-6|
|Fullard, Michelle E; Tran, Baochan; Xie, Sharon X et al. (2016) Olfactory impairment predicts cognitive decline in early Parkinson's disease. Parkinsonism Relat Disord 25:45-51|
|Roalf, David R; Moore, Tyler M; Wolk, David A et al. (2016) Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease. J Neurol Neurosurg Psychiatry :|
|Brettschneider, J; Irwin, D J; Boluda, S et al. (2016) Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type. Neuropathol Appl Neurobiol :|
|Biundo, Roberta; Weis, L; Bostantjopoulou, S et al. (2016) MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. J Neural Transm (Vienna) 123:431-8|
|Lim, Nicholas S; Swanson, Christine R; Cherng, Hua-Ren et al. (2016) Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. Ann Clin Transl Neurol 3:346-55|
|Price, Amy Rose; Peelle, Jonathan E; Bonner, Michael F et al. (2016) Causal Evidence for a Mechanism of Semantic Integration in the Angular Gyrus as Revealed by High-Definition Transcranial Direct Current Stimulation. J Neurosci 36:3829-38|
|Chahine, Lama M; Weintraub, Daniel; Hawkins, Keith A et al. (2016) Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. Mov Disord 31:86-94|
|Tuttle, Marcus D; Comellas, Gemma; Nieuwkoop, Andrew J et al. (2016) Solid-state NMR structure of a pathogenic fibril of full-length human Î±-synuclein. Nat Struct Mol Biol 23:409-15|
|White, Matthew T; Shaw, Leslie M; Xie, Sharon X et al. (2016) Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease. J Alzheimers Dis 51:463-70|
Showing the most recent 10 out of 250 publications